AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02151981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3).
Study identification
- NCT ID
- NCT02151981
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 421 participants
Conditions and interventions
Conditions
Not listed
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2014
- Primary completion
- Apr 14, 2016
- Completion
- Dec 14, 2023
- Last update posted
- Jan 6, 2025
2014 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anaheim | California | 92801 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | Norwalk | Connecticut | 06856 | — |
| Research Site | Gainesville | Florida | 32610 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Pembroke Pines | Florida | 33028 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Park Ridge | Illinois | 60068 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Marrero | Louisiana | 70072 | — |
| Research Site | Chevy Chase | Maryland | 20815 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | Brick | New Jersey | 08724 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Hershey | Pennsylvania | 17033-0850 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02151981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02151981 live on ClinicalTrials.gov.